MassDevice15d
IceCure earns European patent win for next-gen cryoablation tech
IceCure Medical (Nasdaq:ICCM) announced today that it received an intention to grant notice from the European Patent Office.
Nasdaq1mon
IceCure Medical’s Cryoablation Success in Kidney Tumors
IceCure Medical’s ProSense® Cryoablation technology shows promise in treating kidney tumors with an 88.7% recurrence-free rate in patients unable to undergo surgery, based on interim results ...
Nature21d
First guidelines for unilateral cT1 renal tumor management
Advances in minimally invasive techniques have increased our armamentarium to treat cT1 renal masses, especially ... such as radiofrequency ablation and cryoablation, which can be performed ...
Medscape16d
Cryoablation versus Radiofrequency Ablation for Atrioventricular Nodal Reentrant Tachycardia: Patient Pain Perception and Operator Stress
Background: Cryoablation (CRYO) is an alternative to radiofrequency (RF) ablation in the treatment of atrioventricular nodal reentrant tachycardia (AVNRT). This study aims to evaluate the ...
Nature9y
Worse sexual function after cryoablation—a case for EBRT?
External beam radiation therapy and cryoablation can both be used to treat localized prostate cancer. Quality of life outcomes are similar with the two forms of treatment, with the exception of ...
IceCure Medical Secures European Patent for Next-Generation Cryoablation Technology
Icecure Medical ( ) has issued an update. IceCure Medical has received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic system connector t ...